Vanguard Group Inc. Has $97.06 Million Position in 10x Genomics $TXG

Key Points

• Vanguard Group Inc. has increased its stake in 10x Genomics by 1.7%, owning 11,118,086 shares valued at approximately $97.06 million.
• During the first quarter, several hedge funds, including GAMMA Investing LLC and PNC Financial Services Group Inc., significantly increased their holdings in the company.
• 10x Genomics reported earnings of $0.28 per share, surpassing analysts' expectations, with revenue of $172.91 million for the quarter.

Vanguard Group Inc. increased its position in 10x Genomics (NASDAQ:TXG - Free Report) by 1.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,118,086 shares of the company's stock after buying an additional 184,537 shares during the period. Vanguard Group Inc. owned 9.09% of 10x Genomics worth $97,061,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its holdings in 10x Genomics by 81.8% in the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock worth $31,000 after buying an additional 1,614 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in 10x Genomics in the fourth quarter worth approximately $32,000. Signaturefd LLC increased its holdings in 10x Genomics by 134.3% in the first quarter. Signaturefd LLC now owns 4,203 shares of the company's stock worth $37,000 after buying an additional 2,409 shares during the last quarter. Whittier Trust Co. acquired a new position in 10x Genomics in the first quarter worth approximately $41,000. Finally, PNC Financial Services Group Inc. grew its holdings in 10x Genomics by 153.6% during the first quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company's stock valued at $45,000 after purchasing an additional 3,119 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company's stock.

10x Genomics Price Performance

TXG opened at $14.30 on Friday. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $24.76. The firm's fifty day moving average price is $12.59 and its two-hundred day moving average price is $10.68. The company has a market capitalization of $1.78 billion, a P/E ratio of -20.43 and a beta of 2.03.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.63. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The firm had revenue of $172.91 million for the quarter, compared to the consensus estimate of $139.36 million. During the same quarter in the previous year, the company earned ($0.32) earnings per share. The business's revenue was up 12.9% compared to the same quarter last year. 10x Genomics has set its Q3 2025 guidance at EPS. On average, equities research analysts expect that 10x Genomics will post -1.43 EPS for the current fiscal year.

Analysts Set New Price Targets

TXG has been the topic of a number of recent analyst reports. Canaccord Genuity Group set a $16.00 price target on shares of 10x Genomics in a research report on Monday, August 11th. The Goldman Sachs Group lowered their price objective on shares of 10x Genomics from $7.50 to $6.50 and set a "sell" rating on the stock in a research note on Monday, May 12th. Stephens restated an "overweight" rating and issued a $14.00 price objective on shares of 10x Genomics in a research note on Thursday, May 15th. Bank of America raised their price objective on shares of 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a research note on Thursday, June 26th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of 10x Genomics in a research note on Thursday, August 14th. Six analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $13.54.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.